Saturday, June 20, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,771
Drugs linked 4,798

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 883 of 1,261

  1. US 8389557

    Triazole derivatives useful as Axl inhibitors

    Rigel Pharmaceuticals, Inc. · Granted Mar 5, 2013 · Expires Feb 28, 2033

    granted

  2. US 8389502

    Stabilized steroid composition and method for its preparation

    Precision Dermatology, Inc. · Granted Mar 5, 2013 · Expires Feb 28, 2033

    granted

  3. US 8391959

    Composition for improving efficiency of drug delivery

    TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD. · Granted Mar 5, 2013 · Expires Feb 28, 2033

    granted

  4. US 8389736

    Compounds having activity in correcting mutant-CFTR processing and uses thereof

    The Regents of the University of California · Granted Mar 5, 2013 · Expires Feb 28, 2033

    granted

  5. US 8389727

    Solid forms of N-(4-(7-Azabicyclo[2.2.1]Heptan-7-yl)-2-Trifluoromethyl)Phenyl)-4-Oxo-5-(Trifluoromethyl)-1,4-Dihydroquinoline-3-Carboxamide

    Vertex Pharmaceuticals Incorporated · Granted Mar 5, 2013 · Expires Feb 28, 2033

    granted

  6. US 8389679

    Targeted antimicrobial moieties

    The Regents of the University of California · Granted Mar 5, 2013 · Expires Feb 28, 2033

    granted

  7. US 8389731

    Chiral pyrrolidine core compounds en route to inhibitors of nitric oxide synthase

    Northwestern University · Granted Mar 5, 2013 · Expires Feb 28, 2033

    granted

  8. US 8389515

    2,4-pyrimidinediamine compounds and prodrugs and their uses

    Rigel Pharmaceuticals, Inc. · Granted Mar 5, 2013 · Expires Feb 28, 2033

    granted

  9. US 8389759

    Oligomer-anticholinergic agent conjugates

    Nektar Therapeutics · Granted Mar 5, 2013 · Expires Feb 28, 2033

    granted

  10. US 8388933

    Multimeric protein toxins to target cells having multiple identifying characteristics

    The United States of America as Represented by the Secretary of the Department of Health and Human Services · Granted Mar 5, 2013 · Expires Feb 28, 2033

    granted

  11. US 8388963

    Antitumor combinations containing a VEGF-inhibiting agent and 5FU or a derivative thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Mar 5, 2013 · Expires Feb 28, 2033

    granted

  12. US 8383360

    Methods of diagnosing and treating autism

    The Regents of the University of California · Granted Feb 26, 2013 · Expires Feb 21, 2033

    granted

  13. US 8383817

    Benztropine compounds and uses thereof

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Feb 26, 2013 · Expires Feb 21, 2033

    granted

  14. US 8383388

    Modified coagulation factor IX polypeptides and use thereof for treatment

    Catalyst Biosciences, Inc. · Granted Feb 26, 2013 · Expires Feb 21, 2033

    granted

  15. US 8383133

    Conjugates of Plasmodium falciparum surface proteins as malaria vaccines

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Feb 26, 2013 · Expires Feb 21, 2033

    granted

  16. US 8383380

    Segmented polymers and their conjugates

    Nektar Therapeutics · Granted Feb 26, 2013 · Expires Feb 21, 2033

    granted

  17. US 8383132

    Immunostimulatory recombinant intracellular pathogen immunogenic compositions and methods of use

    The Regents of the University of California · Granted Feb 26, 2013 · Expires Feb 21, 2033

    granted

  18. US 8383093

    Subcutaneous delivery of poly(oxazoline) conjugates

    Serina Therapeutics, Inc. · Granted Feb 26, 2013 · Expires Feb 21, 2033

    granted

  19. US 8383102

    Fusion of peptidoglycan hydrolase enzymes to a protein transduction domain allows eradication of both extracellular and intracellular gram positive pathogens

    The United States of America, as represented by the Secretary of Agriculture · Granted Feb 26, 2013 · Expires Feb 21, 2033

    granted

  20. US 8383099

    Adoptive cell therapy with young T cells

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Feb 26, 2013 · Expires Feb 21, 2033

    granted

  21. US 8383654

    Heterocyclic antagonists of prostaglandin D2 receptors

    Panmira Pharmaceuticals, LLC · Granted Feb 26, 2013 · Expires Feb 21, 2033

    granted

  22. US 8383858

    Processes and intermediates for preparing steric compounds

    Vertex Pharmaceuticals Incorporated · Granted Feb 26, 2013 · Expires Feb 21, 2033

    granted

  23. US 8383805

    RNAi modulation of SCAP and therapeutic uses thereof

    The Board of Regents of the University of Texas System · Granted Feb 26, 2013 · Expires Feb 21, 2033

    granted

  24. US 8383785

    Anti-bacterial activity of 9-hydroxy derivatives of 6,11-bicyclolides

    Enanta Pharmaceuticals, Inc. · Granted Feb 26, 2013 · Expires Feb 21, 2033

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.